Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 1996

Filing Date
Filed March 3, 1997
Period End
December 31, 1996
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 3, 1997. Cited figures are marked; the original filing is the authoritative source.

Important correction first: the document provided is Schering-Plough Corporation's (NYSE: SGP) Form 10-K for fiscal year 1996, not Merck & Co. (MRK).

The analysis below covers Schering-Plough. Its 1996 results were strong. Sales rose 11% to $5.66 billiona, driven by 13% volume growth, with price down 1% and currency down 1%.

Income from continuing operations grew 15% to $1.21 billionb, and earnings per share from continuing operations rose 16% to $3.30. The company's pre-tax margin held near 28%, with an effective tax rate of 24.5%. Growth was concentrated in CLARITIN, whose worldwide sales reached $1.15 billion versus $789 million in 1995, along with INTRON A, IMDUR, and CEDAX.

Offsetting this, PROVENTIL sales fell 25% to $316 millionc as generic metered-dose inhalers eroded the franchise. The company's OTC business declined 16%. The balance sheet strengthened, with shareholders' equity rising to $2.06 billion from $1.62 billion and the debt-to-total-capital ratio falling to 30% from 36%.

Operating cash flow was $1.46 billiond, against capital expenditures of $325 million, $388 million of share repurchases, and $474 million of dividends. The quarterly dividend was increased 14% to $0.33 during 1996. Cash and equivalents ended the year at $535 million, and the company reported $1.3 billion in unused credit lines.

R&D spending reached $723 million, about 12.8% of sales. Investors should note the litigation exposure. The company faces 149 lawsuits over synthetic estrogen (DES) with more than $2 billion claimed, more than 160 antitrust actions by pharmacies and consumers, a $400 million suit from the FoxMeyer bankruptcy estate, and an FTC price-fixing investigation.

Management considers material losses beyond accruals remote, but these matters are a key risk. Also note that a $63.6 million THEO-DUR product liability judgment is under appeal.

Key Highlights

  1. Sales grew 11% to $5,655.8 million in 1996, with volume up 13%, partly offset by 1% price declines and 1% unfavorable currency effects.
  2. Income from continuing operations rose 15% to $1,212.8 million; EPS from continuing operations was $3.30, up 16% from $2.85.
  3. CLARITIN worldwide sales reached $1.15 billion, up from $789 million, making it the primary growth driver.
  4. PROVENTIL (albuterol) sales fell 25% to $316 million due to generic inhaler competition, with the new PROVENTIL HFA launch in December 1996 intended to help.
  5. Balance sheet improved: shareholders' equity rose to $2,059.9 million and debt-to-total-capital fell to 30% from 36%; cash rose to $535.1 million.
  6. Cash returned to shareholders: $474.0 million in dividends (up to $1.28 per share) and $388.0 million in share repurchases (5.8 million shares).
  7. Significant litigation exposure: DES lawsuits claiming over $2 billion, antitrust actions (more than 160), a $400 million FoxMeyer suit, and an FTC price-fixing investigation.

Frequently Asked Questions

  1. What drove Schering-Plough's 1996 sales growth?

    Sales of $5.66 billion rose 11%, led by domestic prescription growth of 23%. CLARITIN, the allergy product including CLARITIN-D, was the largest contributor. Domestic anti-infective and anticancer sales rose 33%, supported by INTRON A and the launch of CEDAX. Cardiovascular sales increased 36%, reflecting IMDUR and K-DUR. Over-the-counter sales fell 16% because of private-label competition.

  2. How significant is the generic threat to PROVENTIL?

    It is material. PROVENTIL sales fell 25% to $316 million in 1996, and the filing says generic metered-dose inhalers will continue to hurt future sales and profitability. The company's own Warrick generic inhaler has softened the decline, and the PROVENTIL HFA launch in December 1996 is its main response.

  3. What are the main legal risks disclosed?

    The company faces 149 DES-related lawsuits with more than $2 billion claimed in total, more than 160 antitrust actions, a $400 million FoxMeyer suit, and an FTC investigation into possible price-fixing. Management says material liability beyond accrued amounts is remote for the DES and Superfund matters and denies wrongdoing in the antitrust and FTC matters. A $63.6 million THEO-DUR judgment, including $57.5 million in punitive damages, is also under appeal.

  4. How strong is the company's financial position and capital return policy?

    Operating cash flow was $1.46 billion, comfortably covering $325 million in capital expenditures, $474 million in dividends, and $388 million in buybacks. Debt-to-total-capital fell to 30%, the company held $1.3 billion in unused credit lines, and its commercial paper and bond ratings were A-1+/P-1 and AA/Aa3. The 1996 return on average shareholders' equity was 65.9%, though this is inflated by a small equity base after prior buybacks.